CoChat
Sign Up
Cited by 3,703

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Hans, C. P.·2004·Blood
DOI 10.1182/blood-2003-05-1545
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2003-05-1545

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. A clinical evaluation of the International Lym- phoma Study Group classification of non- Hodgkin's lymphoma. The Non-Hodgkin's Lym- phoma Classification Project. Blood. 1997;89: 3909-3918.
  2. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325-334.
  3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lym- phoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
  4. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. Bcl-2 and other genomic alterations in the prognosis of large-cell lym- phoma. N Engl J Med. 1989;320:1047-1054.
  5. Jacobson JO, Wilkes BM, Kwaiatkowski DJ, Me- deiros LJ, Aisenberg AC, Harris NL. Bcl-2 rear- rangements in de novo diffuse large cell lym- phoma: association with distinctive clinical features. Cancer. 1993;72:231-236.
  6. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer. 1994;69:337-341.
  7. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol. 1994;12:149- 154.
  8. Offit K, Lo Coco F, Louie DC, et al. Rearrange- ment of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994; 331:74-80.
  9. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: cor- relation with histology, immunophenotype, karyo- type, and clinical outcome in 217 patients. Blood. 1994;83:2423-2427.
  10. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population- based study. J Clin Oncol. 1996;14:2131-2138.
  11. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a Brit- ish National Lymphoma Investigation Study. Blood. 1996;88:1046-1051.
  12. Hermine O, Haioun C, Lepage E, et al. Prognos- tic significance of bcl-2 protein expression in ag- gressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-272.
  13. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expres- sion and Bcl-2 gene rearrangement in diffuse ag- gressive non-Hodgkin's lymphoma. Blood. 1997; 90:244-251.
  14. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of bcl-6 and bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol. 1997;183:281- 286.
  15. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrange- ments in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
  16. Vitolo U, Gaidano G, Botto B, et al. Rearrange- ments of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55-61.
  17. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is de- pendent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998; 16:1931-1939.
  18. Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int. 1999;49:1043-1052.
  19. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5 ϩ , and CD5 Ϫ with CD10 ϩ groups may constitute clinically relevant sub- types. Leukemia. 1999;13:1441-1447.
  20. Takeshita M, Iwashita A, Kurihara K, et al. Histo- logic and immunohistologic findings and progno- sis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol. 2000;24:1641-1649.
  21. Akasaka T, Ueda C, Kurata M, et al. Nonimmuno- globulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood. 2000;96:2907-2909.
  22. Kawasaki C, Ohshim K, Suzumiya J, et al. Rear- rangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma. 2001;42:1099-1106.
  23. Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lym- phoma: CD10 is a marker of improved prognosis. Histopathology. 2001;39:156-162.
  24. Lossos IS, Jones CD, Warnke R, et al. Expres- sion of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lym- phoma. Blood. 2001;98:945-951.
  25. Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma. 2001;42:1089-1098.
  26. Llanos M, Alvarez-Arguelles H, Aleman R, Ora- mas J, Diaz-Flores L, Batista N. Prognostic sig- nificance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001; 18:15-22.
  27. Chang CC, Cleveland RP, Perkins SL. CD10 ex- pression and survival [letter]. Am J Clin Pathol. 2002;117:660-661.
  28. Go JH, Yang WI, Ree HJ. CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance. Arch Pathol Lab Med. 2002; 126:956-960.
  29. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136-1143.
  30. Barrans SL, O'Connor SJ, Evans PA, et al. Rear- rangement of the BCL6 locus at 3q27 is an inde- pendent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117: 322-332.
  31. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile as- sessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101: 78-84.
  32. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prog- nostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res. 2003;9:722-728.
  33. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921-1925.
  34. Filipits M, Jaeger U, Pohl G, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res. 2002;8:729- 733.
  35. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403: 503-511.
  36. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after che- motherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
  37. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised ma- chine learning. Nat Med. 2002;8:68-74.
  38. McClintock S, Perkins SL, Cleveland RP, et al. Immunohistochemical expression pattern of ger- minal center and activation B-cell markers corre- lates with prognosis in diffuse large B-cell lym- phoma [abstract]. Mod Pathol. 2003;16:244a.
  39. Hans CP, Weisenburger DD, Gascoyne RD, et al. Classification of diffuse large B-cell lymphoma into prognostically significant subgroups by im- munohistochemistry using a tissue microarray [abstract]. Mod Pathol. 2002;15:243a.
  40. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immu- nohistochemistry. Mod Pathol. 2001;14:686-694.
  41. Hedvat CV, Hegde A, Chaganti RS, et al. Applica- tion of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
  42. Milanes-Yearsley M, Hammond ME, Pajak TF, et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol. 2002; 15:1366-1373.
  43. Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, re- spectively, a highly conserved and a formol-resis- tant epitope on the human BCL-6 protein amino- terminal region. Am J Pathol. 1996;148:1543- 1555.
  44. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
  45. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood. 2002;99:409-426.
  46. Falini B, Fizzotti M, Pucciarini A, et al. A monoclo- nal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal cen- ter B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092.
  47. Peto R, Pike M, Armitage P, Breslow N. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
  48. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.
  49. Kononen J, Bubendorf L, Kallioniemi A, et al. Tis- sue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4: 844-847.
  50. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 anti- gen expression in diffuse large B-cell lymphoma. Am J Clin Pathol. 2001;115:582-588.
  51. Xu Y, McKenna RW, Molberg KH, Kroft SH. Clini- copathologic analysis of CD10 ϩ and CD10 Ϫ dif- fuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol. 2001;116:183-190.
  52. McClure RF, Macon MR, Remstein ED, Dewald GW, Habermann TM, Kurtin PJ. Prognostic mark- ers in adult, de novo, diffuse large B-cell lym- phoma; CD10, bcl-6, bcl-2, and BCL2/IGH [ab- stract]. Mod Pathol. 2003;16:244a.
  53. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence- specific transcriptional repressor. Proc Natl Acad Sci U S A. 1996;93:6947-6952.
  54. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997;8:101-104.
  55. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45-53.
  56. Wang X, Li Z, Naganuma A, Ye BH. Negative au- toregulation of BCL-6 is bypassed by genetic al- terations in diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2002;99:15018-15023.
  57. Pasqualucci L, Migliazza A, Basso K, Houlds- worth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101:2914-2923.
  58. Mamane Y, Heylbroeck C, Genin P, et al. Inter- feron regulatory factors: the next generation. Gene. 1999;237:1-14.
  59. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 ex- pression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14:449-456.
  60. Trzpuc T, Kampalath B, Abed N, et al. Expression of MUM1/IRF4 correlates with prognosis in pa- tients with diffuse large B-cell lymphoma [ab- stract]. Mod Pathol. 2002;15:267a.
  61. Gaidano G, Carbone A. MUM1: a step ahead to- ward the understanding of lymphoma histogen- esis. Leukemia. 2000;14:563-566.
  62. Shu W, Yang H, Zhang L, Lu MM, Morrisey EE. Characterization of a new subfamily of winged- helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem. 2001;276:27488-27497.
  63. Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chro- mosome 3p. Cancer Res. 2001;61:8820-8829.
  64. Jones M, Gerring D, Ott G, et al. The differential expression of proteins in diffuse large B cell lym- phoma [abstract]. Blood. 2001;98:332a.
  65. Teramoto N, Pokrovskaja K, Szekely L, et al. Ex- pression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer. 1999;81:543-550.
  66. Andreasson P, Johansson B, Arheden K, et al. Genomic amplification of CCND2 is rare in non- Hodgkin lymphomas. Cancer Genet Cytogenet. 1998;102:81-82.

Cited by

See all 3,703

Metadata

Authors
Hans, C. P.
Venue
Blood
Publisher
American Society of Hematology
Published
2004-01-01
Volume
103
Issue
1
Pages
275-282
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2003-05-1545
Cited by
3,703
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review